Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07144384 | Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma | completed | Early Phase 1 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04480645 | CivaDerm(TM) Surface Therapy Pilot Study | completed | Early Phase 1 | 10 | CivaTech OncologyINDUSTRY | 1 | Mar 24, 2026 |
| clinicaltrials |
| NCT03276832 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | completed | Early Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03281811 | Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides | completed | Early Phase 1 | 11 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT03430934 | Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor | completed | Early Phase 1 | 11 | University of Missouri-ColumbiaOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Early Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02320305 | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | completed | Early Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01789827 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | completed | Early Phase 1 | 5 | Mayo ClinicOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT02735356 | Topical Itraconazole in Treating Patients With Basal Cell Cancer | completed | Early Phase 1 | 9 | Jean Yuh TangOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT01631331 | Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) | completed | Early Phase 1 | 15 | Stanford UniversityOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01959477 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | completed | Early Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00535769 | Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use | completed | Early Phase 1 | 70 | Massachusetts General HospitalOTHER | 1 | Jul 20, 2012 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials